<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Abumiya M</submitter><funding>Japan Society for the Promotion of Science</funding><pagination>6362</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7973796</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C&lt;sub>0&lt;/sub>) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C&lt;sub>0&lt;/sub> and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C&lt;sub>0&lt;/sub> and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P &lt; 0.001 and r = - 0.315, P &lt; 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = - 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate </pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.</pubmed_title><pmcid>PMC7973796</pmcid><funding_grant_id>20K07150</funding_grant_id><pubmed_authors>Takahashi S</pubmed_authors><pubmed_authors>Yoshioka T</pubmed_authors><pubmed_authors>Miura M</pubmed_authors><pubmed_authors>Takahashi N</pubmed_authors><pubmed_authors>Abumiya M</pubmed_authors><pubmed_authors>Kameoka Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.</name><description>The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C&lt;sub>0&lt;/sub>) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C&lt;sub>0&lt;/sub> and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C&lt;sub>0&lt;/sub> and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P &lt; 0.001 and r = - 0.315, P &lt; 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = - 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2025-04-25T19:22:19.795Z</modification><creation>2025-04-06T07:58:37.197Z</creation></dates><accession>S-EPMC7973796</accession><cross_references><pubmed>33737618</pubmed><doi>10.1038/s41598-021-85757-7</doi></cross_references></HashMap>